Establish scope and registration boundaries
A reproduced notice reports an October 30, 2026 deadline for comments on CMDE’s implantable-neurostimulator review draft. The downloaded copy covers rechargeable and non-rechargeable deep-brain, spinal-cord, sacral-nerve, vagus-nerve and other neurostimulators. It expressly excludes review requirements for closed-loop stimulation.
Evidence for safe and effective use with electrodes, extensions, programmers and charging equipment is distinct from registration-unit determination. The draft considers attributes including power source, rechargeability and MRI conditionality. Combined use does not establish that every component can be registered together.
For the implanted stimulator, the mandatory standards identified include GB 16174.1 and YY 0989.3. Standards for external and associated products depend on their characteristics. A generic medical-electrical-equipment standard does not replace the active-implant applicability assessment.
MRI coverage depends on configurations and scan conditions
Section 4.10.1 addresses combinations of the stimulator, extension where present, and electrodes within the registration unit. Testing a representative model or worst-case configuration requires justification of that selection. Passive implanted components also need relevant verification evidence.
Scan region, field strength, transmit coil and excitation type define further dimensions of coverage. Claims for head or whole-body scanning, 1.5 T or 3 T, and local or whole-body transmit coils require corresponding testing and coverage rationale. Conditional MRI safety is not a claim independent of scan conditions.
A higher field strength does not justify coverage of a lower one merely because it is higher. The draft calls for analysis of risks in both directions, considering the MRI environment and stimulator characteristics and configuration. Coverage of specific test results across field strengths therefore needs a technical explanation.
Modeling provisions address the human model, coil model, excitation, body position and device path, together with information on the simulation software. Simulation results have defined models and conditions; a final value alone does not explain their basis.
The copy recommends reference to ISO/TS 10974, primarily using modeling and bench testing. Animal studies may supplement them where those methods cannot adequately cover the test objective and should not be the routine first choice. This sequence explains the intended evidence approach; adding more study types does not necessarily resolve a coverage gap.
Capacity, warning and programming evidence answer different questions
Non-rechargeable-battery evidence includes total, usable and design capacity, discharge curves under typical conditions, and voltage and remaining capacity at replacement indication. Rechargeable-battery evidence additionally addresses charging parameters, charge/discharge characteristics, cycle count and capacity change. Time, temperature and load also matter.
Battery-management evidence covers state indication, depletion warning, depletion measurement and the interval from warning to loss of power. Capacity research explains available charge; warning verification explains when the device alerts and the remaining period of power. One conclusion does not establish the other.
Wireless charging or powering adds distance, power, efficiency and duration evidence, as well as applicable short-circuit, overcurrent, overvoltage, overtemperature and undervoltage protection. The draft does not support a claim that every design must use one accelerated-aging model.
Programming and communication evidence describes the wireless technology, protocol and functions. For remote programming, the copy expressly requests threat-modeling and penetration-testing research. The requirements relate to the remote function and its risks rather than merely the presence of a wireless connection.
The evidence needs to support the claimed MRI conditions, depletion warnings and remote-programming functions. Final requirements still depend on the authoritative guidance and actual product.
Research status
This article uses the reproduced notice and downloaded draft, with existing CMDE trial review points as background. The current copy has not been authenticated against an original obtained directly from CMDE. The clause explanations and reported deadline retain that limitation.
Sources
- Primary official source植入式神经刺激器注册审查指导原则（征求意见稿）—通知及附件转载 (opens in a new tab)摩熵医药（转载国家药监局医疗器械技术审评中心文本）
- Supporting source植入式神经刺激器技术审评要点（试行） (opens in a new tab)Center for Medical Device Evaluation, National Medical Products Administration